News

Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%. The data “pave the way for a potentially transformative cure,” for a disease that affects more than 1.7...

Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease

Study AER-01-002 uses a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) patients AER-01-002 is well-powered to determine if 28-days of once-daily dosing of fexlamose is safe and improves lung function Fexlamose has been shown in Phase...

ScaleReady awards a G-Rex® Grant to Moonlight Bio

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite process development and IND-enabling studies of their lead CAR T cell...

Alessa Therapeutics Announces Closing $15M Seed Financing

Alessa Therapeutics, a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early interception of cancer and other diseases, announced the closing of a $15M seed financing led by Mission BioCapital joined by Johnson &...

Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines

Chroma Medicine and Nvelop Therapeutics today announced their merger and subsequent launch of nChroma Bio (“nChroma” or “the company”) to redefine the future of genetic medicines. nChroma brings together potent epigenetic editing plus non-viral, programmable delivery to address key limitations in...

Vevo Therapeutics Partners with the Parse Biosciences GigaLab to Generate 100M Cell Atlas for AI Powered Drug Discovery

Parse Biosciences, a leading provider of accessible and scalable single-cell sequencing solutions, today announced the generation of the world’s largest single-cell dataset to date, totaling 100 million cells. This impressive milestone was achieved in just one month using Parse Biosciences’ GigaLab...

Delve Bio Announces Launch of its Groundbreaking Genomic Infectious Disease Test, Delve Detect

Delve Bio, a pioneer in metagenomic sequencing, today announced the commercial launch of 

Exai Bio Announces Publication in Nature Communications Highlighting its Generative AI Liquid Biopsy Platform

Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced a peer-reviewed publication about its generative AI model in Nature Communications. The paper entitled “Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early...

UCSF Joins I-Corps’ New Regional Innovation Hub for the Northwest

Training will help entrepreneurs at UCSF develop their ideas into companies. UC San Francisco is part of a new Northwest Region Innovation Corps (I-Corps) Hub funded by the National Science Foundation to train faculty and student entrepreneurs on how to commercialize their research. ...

Delve Bio and UCSF Publish Research Demonstrating Clinical Utility of Metagenomic Next-Generation Sequencing (mNGS) for Diagnosing Serious Neurological Infections

Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today announced Nature Medicine has published its study demonstrating the clinical utility of mNGS testing to identify difficult-...